Research programme: anti-ED-B fusion proteins - Philogen/Bayer HealthCare
Alternative Names: Immunoconjugates - Bayer Schering Pharma/PhilogenLatest Information Update: 04 Nov 2017
At a glance
- Originator Philogen
- Class Antibodies; Proteins
- Mechanism of Action Angiogenesis inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Italy (Parenteral)
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals